Generic Name and Formulations:
Alglucosidase alfa 5mg/mL; pwd for IV infusion after reconstitution and dilution; preservative-free.
Sanofi Genzyme Company
Indications for MYOZYME:
Pompe disease (GAA deficiency).
Give by IV infusion over 4 hours. Initial infusion rate: 1mg/kg/hr, may increase to 2mg/kg/hr every 30 minutes after tolerance established to max 7mg/kg/hr. 20mg/kg every 2 weeks.
Anaphylaxis, severe allergic, and immune mediated reactions. Risk of cardiorespiratory failure.
Discontinue immediately if severe anaphylactic or allergic reactions develop; have appropriate medical support measures available and during rechallenge. Increased risk of acute cardiorespiratory failure with acute underlying respiratory illness, compromised cardiac function, or sepsis. Cardiac hypertrophy (increased risk of cardiac arrhythmia when given general anesthesia for central venous catheter placement). Infants with cardiac dysfunction may require prolonged observation times. Monitor for development of systemic immune complex-mediated reactions; consider discontinuing if occurs. Monitor for IgG antibody formation every 3 months for 2 years, then annually. Perform LFTs prior to initiation; monitor periodically. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Recombinant human alpha-glucosidase enzyme.
Pneumonia, respiratory failure/distress, catheter-related infection, respiratory syncytial virus infection, gastroenteritis, fever; infusion reactions (temporarily stop or reduce infusion rate; discontinue if severe).
Single-use vial (50mg)—1
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis